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Hepatitis C virus (HCV) is a major cause of chronic hepatitis and liver carcinoma and new
therapies based on novel targets are needed. The tight junction protein claudin 1 (CLDN-1) is
essential for HCV cell entry and spread, and anti-CLDN-1 rat and mouse mAbs are safe and
effective in preventing and treating HCV infection in a human liver chimeric mouse model.
To accelerate translation of these observations into a novel approach to treat HCV infection and
disease in humans, we screened a phage display library of human single-chain antibody
fragments by using a panel of CLDN-1-positive and -negative cell lines and identified phage
specifically binding to CLDN-1. The 12 clones showing the highest levels of binding were
converted into human IgG4. Some of these mAbs displayed low-nanomolar affinity, and inhibited
infection of human hepatoma Huh7.5 cells by different HCV isolates in a dose-dependent
manner. Cross-competition experiments identified six inhibitory mAbs that recognized distinct
epitopes. Combination of the human anti-SRB1 mAb C-1671 with these anti-CLDN-1 mAbs
could either increase or reduce inhibition of cell culture-derived HCV infection in vitro. These
novel human anti-CLDN-1 mAbs are potentially useful to develop a new strategy for anti-HCV
therapy and lend support to the combined use of antibodies targeting the HCV receptors CLDN-1
and SRB1, but indicate that care must be taken in selecting the proper combination.
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INTRODUCTION
Hepatitis C virus (HCV) infection represents a major
public health concern, with approximately 170 million
people chronically infected (Dustin & Rice, 2007), resulting
in about 470 000 deaths each year. HCV chronic infection
leads to fibrosis, cirrhosis and liver carcinoma (50–76 % of
all liver cancers), which are the primary reasons for liver
transplantation (LT), and this is set to increase (Davis
et al., 2003).
The mechanisms by which HCV escapes the immune
response and establishes a chronic infection are not com-
pletely defined. HCV replicates at a high rate (Neumann
et al., 1998) and its RNA-dependent RNA polymerase
lacks proofreading capacity. This results in high genetic
variability and rapid evolution under selection either by
the immune system or in the presence of antiviral drugs.
Combination of pegylated-IFN-a and ribavirin (PegIFN/
RBV) is effective in only about 50 % of patients and is
often poorly tolerated (Manns et al., 2007). New antiviral
drugs (direct-acting antivirals, DAAs) targeting the virus
polymerase or protease, such as telaprevir or boceprevir
(in clinical use since 2011), also show toxic side effects
and their use has been associated with the emergence of
drug-resistant variants (Welsch et al., 2008; Pawlotsky,
2011; Dabbouseh & Jensen, 2013; Liang & Ghany, 2013;
Chung & Baumert, 2014). By early 2015, the US Food
and Drug Administration and the European Medical3These authors contributed equally to this work.
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Agency (EMA) had approved novel DAAs, including a
second-generation protease inhibitor (simeprevir), the
nucleotide polymerase inhibitor sofosbuvir, and the first
HCV-NS5A inhibitor (daclatasvir, EMA approval only).
Thus, new, more potent DAAs are being developed (Paw-
lotsky et al., 2015; Wedemeyer et al., 2015), but it will be
essential to maintain a healthy pipeline of anti-HCV
drugs, focused on a range of viral and host targets, to
ensure that future interventions are not threatened by
antiviral resistance. This is particularly true for patients
that undergo LT for HCV-related liver disease, where
finding appropriate regimens is still challenging (Kwo &
Badshah, 2015).
mAbs are a validated class of therapeutics with proven
safety and efficacy in a number of clinical applications,
and with an established production process. Furthermore,
with the advent of fully human mAbs, there are no risks
of immune reaction against the antibody (Brekke &
Sandlie, 2003; Adams & Weiner, 2005; Imai & Takaoka,
2006; Fuh, 2007). Overall, human mAbs may have superior
safety and pharmacokinetic profiles to the current antivirals
and emerging DAAs, particularly in the highly susceptible
population of HCV-positive LT patients.
Antibodies that are capable of preventing HCV infection
may represent novel therapy in two different settings:
(i) treatment of chronically infected patients with a
combination of mAbs and DAAs to prevent reinfection
by drug-resistant mutants; (ii) treatment of patients under-
going LT, either as a monotherapy or in combination with
DAAs during the anhepatic phase and during the first days
or weeks following transplantation to prevent reinfection of
the graft. One approach would be to use antibodies that
target the virus directly. However, passive immunotherapy
in LT patients with polyclonal antibodies or mAbs against
the viral envelope has so far only achieved transient
reduction in viral loads and has been unable to prevent
reinfection, presumably owing to the high level of hetero-
geneity in the infecting viral population (Davis et al.,
2005; Schiano et al., 2006). In addition, high-density lipo-
protein can reduce the neutralizing effect of anti-HCV
antibodies (Dreux et al., 2006; Voisset et al., 2006), raising
additional concerns about their use being an effective anti-
viral therapy. For these reasons, the recent discovery of cell
surface molecules required for HCV entry may present
novel promising targets complementary to those of DAAs.
Four different cell surface receptors are necessary for HCV
infection of liver cells: the tetraspanin CD81, the human
scavenger receptor class B type I (SRB1), the tight junction
claudin 1 (CLDN-1) and occludin (OCLN) (Scarselli et al.,
2002; Bartosch et al., 2003; Catanese et al., 2007; Evans
et al., 2007; Ploss et al., 2009). mAbs against CD81 and
SRB1 have been shown to inhibit HCV infection in vitro
and in vivo. In particular, we previously showed that the
human anti-SRB1 mAb C-1671 completely prevents infec-
tion and intrahepatic spread of multiple HCV genotypes
in vivo in human liver-chimeric mice (Meuleman et al.,
2012). Human mAbs against CLDN-1 and OCLN have
not been reported yet, but rat, mouse and mouse/human
chimeric anti-CLDN-1 antibodies were found to efficiently
inhibit infection by HCV of major genotypes in cell culture
(Fofana et al., 2010; Yamashita et al., 2015) and some of
them eliminate chronic HCV infection without detectable
toxicity when administered to human liver-chimeric mice
(Fukasawa et al., 2015; Mailly et al., 2015).
Two other members of the CLDN protein family (CLDN-6
and CLD-9) could be used alternatively for cell entry by
those viruses with broad CLDN tropism (Haid et al.,
2014) and thus could be used as additional targets for
therapy. However, while some strains efficiently use
CLDN-6 as well as CLDN-1, some other strains, such as
JFH-1 and J6, solely use CLDN-1 to access cells and this
can explain the efficacy of the above-mentioned anti-
CLDN-1 antibodies.
To circumvent the potential problems associated with non-
fully human antibodies (Getts et al., 2010), we have gener-
ated a panel of novel fully human mAbs endowed with
binding specificity for CLDN-1. These mAbs recognize
different CLDN-1 epitopes and inhibit in vitro infection
of Huh7.5 by different viral isolates. Finally, one of them
strongly increases antiviral potency when used in combin-
ation with the anti-SRB1 mAb C-1671, highlighting the
potential synergistic effect of using antibodies targeting
different HCV receptors.
RESULTS
Selection of CLDN-1-specific single-chain
antibody fragments (scFvs)
The strategy used for the isolation of anti-CLDN-1 scFvs
consisted of multiple selections from an scFv phage library
on CLDN-1-bearing cells, for enrichment of binders, and
CLDN-1-negative cell lines, to eliminate phage that bind
to common cell surface antigens. This approach was
devised to guarantee efficient selection and increase the
number of different clones specifically binding to CLDN-1.
In the first selection scheme, we used human hepatoma
Huh7.5 cells as antigen-positive cells, which naturally
express high levels of CLDN-1 as well as the other HCV
receptors CD81 and SRB1. These cells were chosen because
they can be infected by HCVs representative of different
genotypes (Gottwein et al., 2009) and, therefore, represent
a bona fide source of CLDN-1 displayed in the right con-
formation for HCV recognition and entry. HEK 293 cells
lacking CLDN-1 were used for the subtractive step.
In the other two selections, HEK 293 cells and Chinese
hamster ovary (CHO) cells were either transduced or trans-
fected, respectively, with human CLDN-1, and used for the
positive selection steps, while mock-transduced or mock-
transfected parental cells were used for the subtraction
step. The choice of these two cell lines was based on the
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hypothesis that a possible mechanism for anti-CLDN-1 anti-
viral activity would be the disruption of the interaction
between CLDN-1 and CD81 (Harris et al., 2010; Mailly
et al., 2015) or other HCV receptors; therefore, we reasoned
that using CLDN-1-transfected CHO cells (which do not
express eitherCD81orSRB1)orHEK293cells (not expressing
SRB1) would render the surfaces of interaction of CLDN-1
with other HCV receptors more accessible to scFv binding.
Initially, two rounds of selection were performed either
with Huh7.5 or with HEK 293-CLDN-1 cells in suspension.
Phage exhibiting selective binding to CLDN-1-expressing
cells were submitted to two additional rounds of selection,
either by using the same combination of cells or by crossing
the selection with the other cell line (see Fig. 1a), to further
increase the chance of selecting phage with a high degree of
specificity for CLDN-1.
The third strategy was performed by panning the library
directly on adherent CHO-CLDN-1 cells after the subtrac-
tion of non-specific clones on adherent mock-transfected
CHO cells, in order to select scFvs against CLDN-1 in its
natural environmental within intercellular contacts.
After three or four rounds of selection, individual phage
were tested by ELISA on CLDN-1-negative and -positive
cells to identify CLDN-1-specific binders. Several phage
specifically binding to CLDN-1-positive cells were identi-
fied from all the three strategies (Fig. 1b). All positive
phage were sequenced and 20 different clones were identi-
fied. Specific binding was confirmed by expressing the cor-
responding soluble scFvs and by testing them in cell ELISA
as described for phage (data not shown). Twelve clones
derived from different selections were chosen for further
studies.
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Fig. 1. Selection and screening of positive phage by cell ELISA on CLDN-1-positive and -negative cells. (a) Schematic rep-
resentation of parallel and crossed selection on different cell lines. Positive phage, which selectively bound to each CLDN-1-
positive cell line, were submitted to two additional rounds of selection, using either the same combination of cells or crossing
the selection with the other one. (b) Binding to HEK 293-CLDN-1 of phage selected either by conventional panning on
Huh7.5 or HEK 293-CLDN-1 cells in suspension (black bars), or by crossed selections (grey bars) on both Huh7.5 and HEK
293-CLDN-1 cells and indicated with (X), or by panning on adherent CHO cells (hatched bars) and indicated with (C). As a
control, all the selected phage were tested on control mock-transduced HEK 293 cells (white bars). Error bars indicate SD.
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Generation and characterization of human anti-
CLDN-1 mAbs
The anti-CLDN-1 scFvs were converted into fully human
IgG4 by subcloning the variable regions into two eukary-
otic vectors for the expression of heavy and light chains,
and by transfecting the resulting recombinant plasmids
into EBNA 293 cells. The secreted antibodies were affinity
purified and tested in cell ELISAs for their selective binding
to cells expressing CLDN-1. All the resulting antibodies
specifically recognized CLDN-1 displayed on Huh7.5 cells
and on HEK 293-CLDN-1 cells (Fig. 2a) and immunopre-
cipitated CLDN-1 after binding to Huh7.5 cells (Fig. 2b).
We then determined the apparent affinity of the mAbs by
dose titration in cell ELISA using CLDN-1-transduced
HEK 293 cells. Ten mAbs displayed good apparent affin-
ities in the low-nanomolar range (0.3–16 nM; Fig. 2c),
while mAbs E9C and C10C showed a lower binding affinity
(Kapp5117 and 190 nM, respectively).
Anti-CLDN-1 mAbs inhibit Huh7.5 infection by
HCV from different strains
The anti-CLDN-1 mAbs were tested for their ability to
inhibit HCV infection of cultured Huh7.5 hepatocytes.
With this aim, cell culture-derived HCV (HCVcc) from
five different HCV strains representative of genotypes 1
and 2 were used: the reference cell culture-adapted Japan-
ese fulminant hepatitis 1 clone JFH-1 (gt2a), two chimeric
viruses [J6/JFH-1 (envelope proteins from gt2a) and H77/
JFH-1 (envelope proteins from gt1a)], and two additional
JFH-1 chimeras generated by using clinically relevant
gt2b glycoproteins from patient-derived isolates – 2B1.1/
JFH-1 and 2B2.8/JFH-1.
Five out of 12 mAbs inhibited all five isolates, although to a
different degree (B9X, D10X, E9C, F7C and H9C), while
mAb A2 was effective against four HCVcc isolates
(Fig. 3). All other mAbs did not show significant inhibitory
effects (data not shown). Three of the active mAbs – A2,
B9X and D10X – showed an overall higher potency, with
low and comparable IC50 values (lower than 20 mg ml
21)
against two isolates from different genotypes, 1a (H77/
JFH-1) and 2a (JFH-1), with the latter mAb displaying
high inhibition also against the J6/JFH-1 virus (Fig. 3
and Table 1). As controls, neutralization curves were per-
formed with another anti-HCV receptor C-1671 mAb
(anti-SRB1), with 1 : 7 mAb (anti-HCV envelope) and
anti-tetanus toxin IgG (isotype-matched irrelevant control)
(Fig. 4a). The 1 : 7 mAb showed IC50 values comparable
with those of B9X and D10X on some strains, such as
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Fig. 2. Binding affinity and specificity of the novel anti-CLDN-1 mAbs. (a) Binding of the 12 novel anti-CLDN-1 mAbs (at a
concentration of 100 nM) to Huh7.5 (black bars), mock-transduced HEK 293 (white bars) and HEK 293-CLDN-1-trans-
duced cells (grey bars). Error bars indicate SD. (b) Western blotting analyses with the commercial murine anti-CLDN-1 mAb
of lysates of CLDN-1-positive and -negative cells previously immunoprecipitated with each mAb. Lane 1, HEK 293 cell
extract; lane 2, HEK 293-CLDN-1 cell extract; lane 3, HEK 293-CLDN-1 cell extract pre-cleared with protein A-Sepharose;
lane 4, aliquot of protein A-Sepharose incubated with HEK 293-CLDN-1 cell extract; lanes 5–18, HEK 293-CLDN-1 cell
extract immunoprecipitated with commercial anti-CLDN-1 (C-terminus), anti-CLDN-1 (loop I), or each selected mAb, A2, B9,
C6, C8, B9X, D10X, A11X, D12C, H9C, F7C, E9C, C10C, respectively; lane 19, HEK 293 cell extract immunoprecipitated
with an anti-CLDN-1 mAb; lane 20, HEK 293-CLDN-1 cell extract immunoprecipitated with an irrelevant IgG. (c) Kapp values
obtained from the binding curves of the 12 anti-CLDN-1 mAbs to HEK 293-CLDN-1 cells.
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Fig. 3. Neutralization curves of the six novel anti-CLDN-1 antibodies. The mAbs were tested on Huh7.5 cells treated with
2B2.8 (.), JFH-1 (X), J6/JFH1 (&), 2B1.1 (m) and H77/JFH-1 (¤). All the mAbs had neutralization capabilities against the
isolates tested. Antibody preparations were pre-incubated at the indicated concentrations with Huh7.5 cells for 1 h. Cells
were thoroughly washed with PBS and virus was added to the cells. Infection was determined by staining for NS5A after
72 h. Statistical analyses were performed at 100 mg ml21 via one-way ANOVA with Bonferroni correction. ****P,0.0001.
Error bars indicate SD.
Table 1. Comparison of binding affinity and inhibition activity of the anti-CLDN-1 mAbs
Kapp values obtained by ELISAs on CLDN-1-positive cells and IC50 values calculated by the inhibition curves of the indicated HCV isolates for the
six human anti-CLDN-1 mAbs.
mAb Kapp (nM) IC50 (mg ml
21)
H77/JFH-1 JFH-1 2B1.1/JFH-1 2B2.8/JFH-1 J6/JFH-1
A2 16.0 14 18 .100 .100 68
B9X 13.0 9 6 63 65 64
D10X 2.9 11 8 57 61 17
H9C 0.8 52 45 32 20 55
E9C 117.2 35 44 56 31 95
F7C 0.9 21 34 57 62 53
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Fig. 4. Neutralization curves of control antibodies and schematic representation for the competitive binding of the six
anti-CLDN-1 antibodies. (a) As controls, neutralization assays were performed with anti-SRB1 receptor C-1671 mAb (D),
anti-HCV envelope 1 : 7 mAb (&) and anti-tetanus toxin IgG irrelevant control (¤). The mAbs were tested on Huh7.5 cells
treated with 2B2.8, JFH-1, J6, 2B1.1 and H77/JFH-1 as described for Fig. 3. Statistical analyses were performed at 100 mg
ml21 via one-way ANOVA with Bonferroni correction. ****P,0.0001. Error bars indicate SD. (b) Percentage binding of each
anti-CLDN-1 clone was calculated as the ratio of the absorbance (at 450 nm) of each bound scFv-phage detected in the
absence or in the presence of the indicated mAbs.
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H77/JFH-1 and JFH-1, whereas for C-1671, owing to its
different mode of action, the IC50 values are typically
lower. As expected, the control anti-tetanus toxin IgG did
not show significant effects.
All six inhibitory anti-CLDN-1 mAbs recognize
different CLDN-1 epitopes
There was no correlation between the binding affinity to
CLDN-1 and the IC50 of the six active mAbs (Table 1),
suggesting that they recognize different epitopes on
CLDN-1. To test this hypothesis we performed cross-
competition ELISAs on Huh7.5 cells. In a first series of
experiments anti-CLDN-1 mAbs were pre-incubated with
Huh7.5 cells at saturating concentrations and then further
incubated with phage displaying the different scFvs. For all
six clones, binding of the phage was significantly inhibited
only by the homologous mAb (Fig. 4b). These results were
confirmed by labelling all six mAbs with biotin and by
competitive ELISA performed by measuring cell binding of
each biotinylated mAb in the absence or presence of all
other six unlabelled mAbs (data not shown). These data
strongly suggested that all six mAbs were able to bind to
different epitopes on the extracellular region of CLDN-1.
Different combinations of anti-CLDN-1 mAbs and
the human anti-SRB1 mAb C-1671 resulted in
either strong synergistic or antagonistic inhibitory
activity
Anti-HCV E2 and anti-CD81 antibodies were previously
shown to improve their inhibitory activity when used in
combination (Ashfaq et al., 2011). To investigate whether
this would also be the case with antibodies targeting differ-
ent HCV receptors, we tested B9X, D10X and the
anti-SRB1 mAb C-1671 alone and also in combination to
determine the combination index (CI). The results of this
experiment were evaluated by the median effect analysis
method using the CompuSyn program (Chou, 2006) to
calculate the CI. CI valuesv0.9, 0.9–1.1 andw1.1 indicate
synergy, an additive effect and antagonism, respectively.
As shown in Fig. 5, the combination of D10X and C-1671
showed moderate or strong synergistic activity at IC50, IC75
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Fig. 5. Combinatorial treatment of D10X and B9X with the anti-SRB1 C-1671 mAb. (a) Inhibition curves (obtained on
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and IC90 against the J6 (0.24 at IC90), 2B1.1 (0.66 at IC90),
2B2.8 (0.56 at IC90) and H77 (0.48 at IC90) chimeras,
whereas the combination of B9X with C-1671 was antagon-
istic for all the viruses tested (w1.5 for all IC values).
To test whether the antagonism between B9X and C-1671
was due to an unexpected capacity of B9X to hinder the
interactions of C-1671 with the hepatocytes, a competitive
ELISA was performed by measuring the binding to Huh7.5
cells of biotinylated anti-SRB1 mAb in the absence or pres-
ence of the unlabelled D10X or B9X mAbs. Simultaneous
binding of anti-CLDN-1 and anti-SRB1 mAbs revealed
that the two mAbs did not interfere in their interactions
with their respective receptors (Fig. 6a).
To test whether the different mechanism of action of D10X
and B9X was due to a different ability of these anti-CLDN-
1 mAbs to induce CLDN-1 endocytosis and thus be intern-
alized by hepatocytes, we analysed their presence in the
lysate of treated cells. Briefly, Huh7.5 cells were incubated
with D10X or B9X mAbs (10 mg ml21) for 2 h at 37 uC,
stripped of surface-bound protein with a low pH glycine/
NaCl buffer, and lysed.
Aliquots of cell extracts containing equal amounts of
protein were analysed by immunoblotting using goat
HRP-conjugated anti-human IgG. As shown in Fig. 6(b),
an immunoreactive band with the molecular mass expected
for the IgG was clearly observed in the intracellular fraction
of cells treated with D10X. The signal intensity was much
stronger than that observed for cells treated with B9X,
whereas no signal was detected in the extracts of untreated
control cells or control cells treated with an irrelevant iso-
type-matched control antibody.
These results indicate that D10X can induce CLDN-1
endocytosis more efficiently than B9X and that this could
be at least in part responsible for their different mechanism
of action.
All six inhibitory anti-CLDN-1 mAbs do not show
toxicity in cell culture
To address potential toxic effects of anti-CLDN-1 mAbs
in vitro, we performed cell viability and lysis analyses on
Huh7.5 cells treated with the six mAbs with anti-HCV
inhibitory activity. Following incubation of hepatoma
cells with each of the anti-CLDN-1 antibodies for 72 h at
37 uC, tests based on 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and lactate dehydro-
genase (LDH) release were carried out. As shown in Fig. 7,
no toxic effects were observed up to high mAb concen-
trations (100 mg ml21).
DISCUSSION
The tight junction protein CLDN-1 is an essential receptor
for HCV infection of human hepatocytes in vitro and
in vivo (Fofana et al., 2010; Mailly et al., 2015). Recently,
it was shown that rat, mouse and human/mouse hybrid
mAbs are effective against HCV infection in vitro and
in vivo without detectable toxicity when administered to
human liver-chimeric mice (Fukasawa et al., 2015; Mailly
et al., 2015). Thus, antibodies against CLDN-1 could rep-
resent a novel class of anti-HCV drugs to be used alone
or in combination with DAAs for treatment of chronic
hepatitis C and to prevent reinfection of liver allografts
in LT patients.
A critical step to be taken toward this end would be to gen-
erate human anti-CLDN-1 mAbs with similar character-
istics to those described, but amenable to clinical use in
humans in light of potential unwanted anti-rat or anti-
mouse IgG immune responses, which are likely to reduce
efficacy of the treatment. We report here the successful
generation by phage display technology of six novel fully
human anti-CLDN-1 mAbs capable of selectively binding
to CLDN-1 displayed on cells and of inhibiting infection
of cultured Huh7.5 cells by five different HCVccs represen-
tative of genotypes 1 and 2.
To generate human mAbs against human CLDN-1, we
selected human scFvs from a phage display library with
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Fig. 6. Mechanism of action of D10X and B9X. (a) Competitive
ELISA of D10X or B9X with anti-SRB1 C-1671 mAb. The per-
centage binding to Huh7.5 cells of biotinylated anti-SRB1 mAb in
the absence or presence of unlabelled anti-CLDN-1 D10X or
B9X mAbs was detected with HRP-streptavidin. (b) Internaliz-
ation of anti-CLDN-1 mAbs. The intracellular levels of the anti-
bodies in target cells were measured by Western blotting with an
HRP-conjugated anti-human IgG. Lanes 1–4: immunoreactive
proteins in the extracts of cells untreated (lane 1) or treated with
B9X (lane 2), with D10X (lane 3) or with unrelated control anti-
body (lane 4). Error bars indicate SD.
Human anti-claudin 1 mAbs for HCV therapy
http://jgv.microbiologyresearch.org 89
Downloaded from www.microbiologyresearch.org by
IP:  128.243.149.219
On: Thu, 26 Jan 2017 13:43:06
alternate cycles of positive selection on CLDN-1-positive
cells and of subtraction with CLDN-1-negative cells to
eliminate phage-binding to other cell surface proteins.
While being more laborious, this strategy of library pan-
ning on live cells offers the advantage of the target protein
being in its native conformation (Sasso et al., 2015). Using
this approach, we previously succeeded in generating
human mAbs with in vitro and in vivo biological activity
against the transferrin receptor, the ErbB2 and EphA2 tyro-
sine kinase receptors and the HCV receptor SRB1 (De Lor-
enzo et al., 2002; Catanese et al., 2007; Ansuini et al., 2009;
Khalaj-Kondori et al., 2011).
The selected scFvs were converted into fully human IgG4
because this isotype was shown to have reduced comp-
lement and cell-mediated cytotoxicity, while displaying
long half-life (Vidarsson et al., 2014). All resulting
human mAbs conserved their specificity of binding to
cell-displayed CLDN-1, with the majority of them showing
apparent affinities in the low-nanomolar range, and did
not show cytotoxic activity when incubated with human
hepatoma cells in vitro.
Six out of 12 mAbs (A2, B9X, D10X, E9C, F7C and H9C)
inhibited infection of human hepatoma Huh7.5 by five
different HCV isolates representing different genotypes
and subtypes in a dose-dependent manner. All but one of
these mAbs, mAb A2, were active against all five viruses
tested, though with different potency, ranging from 6 to
over 50 mg ml21, and with H77/JFH-1 and JFH-1 being
on average the most sensitive isolates.
The ability of anti-CLDN-1 human mAbs to inhibit infec-
tion by different HCV isolates was not unexpected and was
in line with previous observations made with rat and
mouse anti-CLDN-1 antibodies (Fofana et al., 2010; Fuka-
sawa et al., 2015; Mailly et al., 2015; Yamashita et al.,
2015). Most importantly, mAbs B9X and D10X displayed
binding affinity for cell-displayed CLDN-1 and IC50 values
comparable with the rat anti-CLDN-1 mAb OM-7D3,
which was recently shown to prevent HCV infection and
to clear persistent infection in a human liver-chimeric
mouse model without detectable toxicity (Mailly et al.,
2015).
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Fig. 7. Cytotoxic effects on Huh7.5 cells of the anti-CLDN-1 mAbs and their competitive binding with anti-SRB1 mAb. (a)
Percentage cell lysis after incubation with each indicated anti-CLDN-1 mAb; as positive control, cells were treated with 1 %
Triton X-100. (b) Percentage of cell viability after 72 h incubation with each indicated anti-CLDN-1 mAb measured by MTT.
Error bars indicate SD.
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Interestingly, there was no correlation between the binding
affinity and the inhibition activity since the mAb showing
the highest binding affinity (i.e. mAb F7C) was less effect-
ive at inhibiting infection than mAbs A2, B9X and D10X.
These data, together with the observation that only half
of the tested mAbs showed inhibition activity against
HCV infection, suggested that the selected scFvs recognize
different CLDN-1 epitopes. Cross-competition experi-
ments between the six active mAbs confirmed this hypoth-
esis and further validated our selection strategy on different
cell lines aimed at identifying a large number of different
binders specific for different epitopes of CLDN-1.
We also investigated whether the CLDN-1 antibodies B9X
and D10X could synergize with the anti-SRB1 antibody
C-1671, which potently inhibits infection and spread
in vivo in the human liver-chimeric mouse model
(Meuleman et al., 2012). Combination of C-1671 with
D10X resulted in measurable synergy when tested against
four virus strains, including two clinically derived isolates.
In contrast, combination of the anti-SRB1 mAb with B9X
resulted in reduced efficacy despite the absence of binding
interference of the two mAbs to their respective targets.
To explain the different mechanisms of action of B9X and
D10X, we tested their ability to induce CLDN-1 endocyto-
sis by measuring their internalization in treated hepato-
cytes. D10X induces CLDN-1 endocytosis more efficiently
than B9X, and thus the hypothesis can be made that it
could neutralize the infection not only by blocking virus
binding and cell entry (like C-1671) but also in the post-
entry events within the endosomes, thus potentiating the
effects of anti-SRB1 antibody more efficiently than B9X.
Another promising antiviral approach is represented by the
combination of DAAs and viral cell entry inhibitors.
A recent report (Xiao et al., 2015) showed that combining
DAAs and anti-CLDN-1 or anti-SRB1 mAb results in
synergy in treatment of HCV infection either in vitro or
in vivo. Thus, even if the efficacy of our anti-CLDN-1 anti-
bodies is lower [half-maximal effective concentration
(EC50) ranging from 6 to over 50 mg ml
21] than that
showed for DAAs (EC50 ranging from 0.01 mg ml
21 for
simeprevir to 0.5 mg ml21 for boceprevir in in vitro assays
of Huh7.5.1 cells infected with HCVcc), they could be
useful for combinatorial treatment, which might be prom-
ising for prevention of liver graft infection.
The human anti-CLDN-1 mAbs described here represent
a first step toward development of potent HCV entry
inhibitors for clinical use. To this end, we are currently
generating a second generation of anti-CLDN-1 anti-
bodies by affinity maturation. In any case, the data pre-
sented in this work provide for the first time, to the
best of our knowledge, clear-cut evidence for synergistic
activity of anti-CLDN-1 and anti-SRB1 antibodies,
useful for developing more effective anti-HCV therapy,
whilst at the same time highlighting the need for careful
screening of the right combination prior to further
development.
METHODS
Cell cultures. The human embryonic kidney HEK 293T and HEK
293-EBNA, and the human hepatoma Huh7.5 cell lines were cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies)
with the addition of non-essential amino acid solution (Gibco). HEK
293T cells transduced with the gene encoding CLDN-1 were grown in
DMEM containing blasticidin (2 mg ml21; Gibco). CHO cells
(American Type Culture Collection) were cultured in F12 medium
(Gibco). Media were supplemented with 10 % FBS, 50 U penicillin
ml21, and 50 mg streptomycin ml21 (all from Gibco).
Antibodies. The following antibodies were used: mouse HRP-
conjugated anti-M13 mAb (GE Healthcare Bio-Sciences), mouse
HRP-conjugated anti-c-myc-tag mAb (Miltenyi Biotec), mouse anti-
CLDN-1 (C-terminal end) mAb (Life Technology), rabbit anti-loop 1
of CLDN-1 polyclonal antibody (Abcam), goat HRP-conjugated anti-
human IgG (Promega), goat HRP-conjugated anti-human Fc mAb
(Immuno Reagents).
Preparation of phage particles from the phagemid library.
Phage particles were recovered from the library by using the helper
phage M13-K07, as described previously (De Lorenzo et al., 2002).
Phage were purified, concentrated by two steps of polyethylene
glycol (PEG) precipitation (Sambrook et al., 1989) and washed with
20 ml sterile water. After an additional PEG-precipitation step, phage
were resuspended in PBS and centrifuged at 17 500 g for 15 min
at 4 uC.
Selection of scFv-phage on live cells. The human Huh7.5 cell
line, naturally expressing high levels of CLDN-1, the HEK 293T cells
mock-transduced or transduced with CLDN-1, and the CHO cells
mock-transfected or transfected with the vector encoding CLDN-1
were detached by using cell dissociation solution (Sigma-Aldrich) and
washed twice with PBS. For each round of panning, phage (1013 c.f.u.)
were blocked with 5 % milk powder (Sigma-Aldrich) in PBS for
15 min. The blocked phage were submitted to two more rounds of
negative selection by two successive incubations with CLDN-1-
negative cells (5|106), carried out by gently rotating the suspension
for 2 h at 4 uC. The unbound phage, collected by centrifugation at
350 g min21 for 10 min, were then used for the positive selection
performed by using CLDN-1-transduced HEK 293T (1|106) or
Huh7.5 cells (1|106), incubated for 16 h by gently rotating at 4 uC.
Cells were then recovered by centrifugation at 350 g for 10 min and
washed twice with PBS. The positive selection on CLDN-1-transfected
CHO cells was carried out by incubating the phage with 2|106
adherent cells. After extensive washes, bound phage from each
selection were eluted from positive cells with a solution of 1 mg trypsin
(Sigma-Aldrich) ml21, which was then stopped by the addition of
complete EDTA-free protease inhibitor (Roche Diagnostic). The
recovered phage were amplified by infecting E. coli TG1 cells to
prepare phage for the next round of selection.
Characterization of selected scFv-phage. A TG1 culture was
infected with the eluted phage (after three or four rounds of panning)
and plated on 2| TY/agar containing glucose (1 %) and ampicillin
(100 mg ml21). Individual clones were picked, transferred into 96-well
plates and grown for the production of scFv-phage by superinfection
with M13-K07 helper phage encoding trypsin-cleavable pIII. The
plates were centrifuged at 350 g for 30 min at 4 uC to pellet the
bacteria, and aliquots of 50 ml scFv-phage-containing supernatants
were used for cell ELISA. The cDNA encoding the scFv of ELISA-
positive clones was PCR-amplified and sequenced (Bio-Fab
Research), then aligned by using GENTLE software (Magnus Manske,
University of Cologne, Germany). Cultures of E. coli SF110 infected
with anti-CLDN-1 scFv-phage were used for the expression of soluble
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scFvs, which were purified on immobilized-metal affinity chroma-
tography, as described previously (De Lorenzo et al., 2002).
Production and purification of mAbs. For the conversion of the
selected scFvs into whole IgG4, an In-Fusion HD cloning kit (Clon-
tech Laboratories) was used. PCR products were purified and inserted
in the appropriate vectors expressing the constant antibody heavy and
light chains by using the In-Fusion HD Enzyme Premix (Clontech
Laboratories), according to the manufacturer’s recommendations.
The variable heavy chain (VH) sequences were cloned in the linear-
ized PEU 8.2 vector and the variable light chain (VL) sequences were
cloned in linearized PEU 4.2 vector. A sequence analysis was then
performed to confirm the successful cloning of the inserted sequence
with the correct reading frame. Aliquots of 10 mg of the recombinant
vectors encoding each VH and VL pair were co-transfected in HEK
293-EBNA by using Lipofectamine transfection reagent (Life Tech-
nologies) and grown for 10 days at 37 uC. The antibodies secreted into
the medium were purified by using HiTrap Protein-A HP (GE
Healthcare Life Sciences).
Cell ELISAs and competition analysis. To confirm the binding
specificity for CLDN-1 of the selected scFv-phage or purified mAbs,
cell ELISA was carried out by using CLDN-1-positive and -negative
cells as previously described (De Lorenzo et al., 2002). To determine
whether the novel mAbs recognize different CLDN-1 epitopes,
CLDN-1-positive cells, detached with non-enzymic cell dissociation
solution (Sigma-Aldrich), were resuspended in PBS/BSA (6 %),
plated in 96-well plates (1|105 cells in each well) and incubated for
90 min with 200 nM each mAb in PBS/BSA (3 %), with agitation, at
room temperature. Then the cells were resuspended in 100 ml each
scFv-phage (1|1011 c.f.u.) prepared in a PBS/milk (2.5 %) solution
and incubated for further 2 h, with agitation, at room temperature,
before the bound phage was detected (De Lorenzo et al., 2002) with a
mouse HRP-conjugated anti-M13 mAb (GE Healthcare). To deter-
mine whether the novel mAbs B9X and D10X interfere in the binding
of C-1671 to the cells, Huh7.5 cells were incubated with each un-
labelled mAb (200 nM) as described above and then further treated
for 1 h with biotinylated anti-SRB1 mAb (1 nM), which was then
detected with HRP-streptavidin (Bio-Rad).
Cell lysis, immunoprecipitation and Western blot analyses.
CLDN-1-positive cells (2.5|107) were lysed as described previously
(De Lorenzo et al., 2002). Each cell lysate was pre-cleared with protein
A-Sepharose, then incubated at 4 uC for 16 h by gently rotating with
5 mg mouse anti-C-terminal region of CLDN-1 mAb (Life Technol-
ogy), 5 mg rabbit anti-loop 1 of CLDN-1 polyclonal antibody
(Abcam) or 10 mg each mAb selected by phage display. Each immune-
complex was collected by adsorption to protein A-Sepharose and
analysed by Western blotting as previously described (Laemmli, 1970;
Palmer et al., 1999) by using a mouse anti-C-terminal region of
CLDN-1 mAb (Life Technology).
Intracellular anti-CLDN-1 antibodies were detected by Western
blotting of treated Huh7.5 cell extracts with goat HRP-conjugated
anti-human IgG (Promega), The signal was visualized by enhanced
chemiluminescence detection (ECL Western blotting detection kit;
Amersham Biosciences). The signal intensity of reactive bands was
measured with a phosphorimager (GS-710; Bio-Rad).
HCVcc generation, neutralization and combination assays. All
chimeras were produced as previously described (Lindenbach et al.,
2005). Neutralization assays were performed by seeding Huh7.5 cells
(1.5|105) in a 96-well plate (BD Biosciences). After 24 h, each mAb
was added to cells, incubated for 1 h at 37 uC with 5 % CO2, and
washed twice with PBS. Virus was then added and incubated at
37 uC for 72 h. Infected cells were visualized by NS5A staining
(Tellinghuisen et al., 2008) and the infectivity was defined as the
percentage of stained foci compared with an untreated control cul-
ture. Synergistic, additive or antagonistic interaction by the antibodies
for virus neutralization was evaluated by the median effect analysis
method, as previously described (Chou, 2006; Lacek et al., 2014),
using the CompuSyn software (ComboSyn). CI values of v0.9, 0.9–
1.1 and w1.1 indicate synergy, an additive effect and antagonism,
respectively.
Cell viability and cytotoxicity assays. Huh7.5 cells were seeded in
96-well plates at a density of 1|104 per well and incubated at 37 uC
with 5 % CO2 for 16 h. After the addition of 20 or 100 mg ml
21 mAbs
to the culture medium, cells were incubated for a further 72 h. Viable
cells were counted by the trypan blue exclusion test and cell survival
was expressed as a percentage of viable cells in the presence of the
mAb under test with respect to negative control cultures grown in the
absence of the protein. Cell lysis was determined by measuring the
release of LDH using an LDH detection kit (Roche Diagnostic). Lysis
was calculated as the percentage of cytolysis measured in the presence
of each mAb, taking as 100 % the maximal LDH release, determined
by lysis of target cells treated with 1 % Triton X-100.
Statistical analyses and reproducibility of results. Typically, the
reported values were obtained from at least three independent ex-
periments in which three determinations were performed for each
sample. Standard deviations were calculated on the basis of the results
obtained from all the experiments. Results are expressed as the
mean+SD. Statistical analyses were performed via one-way ANOVA
with Bonferroni correction.
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